VIVUS Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range
52-Week Range N/A
Volume2.03 million shs
Average Volume1.44 million shs
Market Capitalization$7.33 million
P/E RatioN/A
Dividend YieldN/A

Receive VVUS News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVUS and its competitors with MarketBeat's FREE daily newsletter.

VIVUS logo


VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.14 out of 5 stars

Medical Sector

567th out of 842 stocks

Pharmaceutical Preparations Industry

250th out of 324 stocks

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

VIVUS (NASDAQ:VVUS) Frequently Asked Questions

What stocks does MarketBeat like better than VIVUS?

Wall Street analysts have given VIVUS a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but VIVUS wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were VIVUS's earnings last quarter?

VIVUS, Inc. (NASDAQ:VVUS) released its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.80) by $0.31. The biopharmaceutical company earned $19.63 million during the quarter.
View VIVUS's earnings history

When did VIVUS's stock split? How did VIVUS's stock split work?

Shares of VIVUS reverse split on the morning of Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 10th 2018. An investor that had 100 shares of VIVUS stock prior to the reverse split would have 10 shares after the split.

Who are VIVUS's key executives?

VIVUS's management team includes the following people:
  • John P. Amos, Chief Executive Officer & Director
  • Mark K. Oki, Chief Financial & Accounting Officer, Senior VP
  • Santosh T. Varghese, Chief Medical Officer & Senior Vice President
  • Ted Broman, Vice President-Chemistry, Manufacturing & Control
  • Tracy Guo, Vice President-Finance

Who are some of VIVUS's key competitors?

What other stocks do shareholders of VIVUS own?

What is VIVUS's stock symbol?

VIVUS trades on the NASDAQ under the ticker symbol "VVUS."

How much money does VIVUS make?

VIVUS has a market capitalization of $0.00 and generates $69.76 million in revenue each year. The biopharmaceutical company earns $-31,500,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis.

How many employees does VIVUS have?

VIVUS employs 57 workers across the globe.

What is VIVUS's official website?

The official website for VIVUS is

Where are VIVUS's headquarters?

VIVUS is headquartered at 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008.

How can I contact VIVUS?

VIVUS's mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at (650) 934-5200 or via email at [email protected]

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.